WHO Publishes Essential Diagnostic Test Package for Bacterial and Fungal Infections and Antimicrobial Resistance

The World Health Organization (WHO) has published a new Essential Package of Diagnostic Tests for Bacterial and Fungal Infections and Antimicrobial Resistance (EPD–AMR), providing countries with a structured framework for prioritising diagnostic testing across different levels of the health system.

The package is intended to improve access to reliable diagnostics, support appropriate antimicrobial use, strengthen antimicrobial resistance surveillance and improve patient outcomes.

WHO describes the EPD–AMR as a prioritised catalogue of in vitro diagnostic tests that should be available across different health-care levels to support diagnosis, treatment and surveillance of bacterial and fungal infections and antimicrobial resistance.

Diagnostics as a Core Component of the AMR Response

WHO highlights that access to accurate diagnostic testing is critical to controlling antimicrobial resistance.

Appropriate testing can help:

  • guide antimicrobial treatment;

  • reduce unnecessary antibiotic use;

  • identify bacterial and fungal infections;

  • support antimicrobial susceptibility testing;

  • generate surveillance data;

  • improve patient outcomes.

However, WHO notes that access to bacteriology and mycology diagnostics remains limited in many settings, particularly in low- and middle-income countries.

Built on the WHO Essential Diagnostics List

The new EPD–AMR builds on the WHO Model List of Essential In Vitro Diagnostics (EDL).

Rather than creating a separate essential diagnostics list, the package is intended to operationalise and complement the EDL by defining which diagnostic tests should be available at different levels of the health system.

WHO identifies three main objectives:

  1. define which diagnostic tests should be available at each health-care level;

  2. specify relevant specimen types and testing methods from primary care through tertiary hospitals;

  3. support implementation of bacteriology and mycology diagnostic services.

A Tiered Health-Care Approach

One of the central features of the EPD–AMR is its tiered model of diagnostic availability.

Tests are assigned according to where patients receive care and samples are collected:

  • primary care;

  • Level 1 hospitals;

  • Level 2 hospitals;

  • Level 3 hospitals.

The approach reflects differences in infrastructure, personnel, equipment and clinical complexity.

Simpler tests are generally prioritised at lower health-care levels, while more complex microbiology and molecular techniques are concentrated at higher-level facilities.

Primary Care

At the primary-care level, WHO prioritises simpler tests that can be performed with limited infrastructure.

Examples include:

  • syphilis serology;

  • urine dipstick testing;

  • rapid testing for Vibrio cholerae;

  • rapid Group A Streptococcus antigen testing;

  • cryptococcal antigen testing;

  • tuberculosis rapid diagnostic testing, including rifampicin resistance detection;

  • lateral flow urine LAM testing in selected patients with HIV.

WHO’s framework recognises that primary-care facilities may have limited laboratory infrastructure and therefore emphasises rapid and relatively simple technologies.

Level 1 Hospitals

Level 1 hospitals build on the primary-care package by introducing more traditional clinical microbiology capability.

Recommended testing includes:

  • urine microscopy;

  • Gram staining;

  • cerebrospinal fluid microscopy;

  • blood cultures;

  • sterile body fluid cultures;

  • bacterial and yeast identification;

  • antimicrobial susceptibility testing;

  • additional TB testing for selected sterile fluids and respiratory specimens.

This level introduces broader use of culture-based testing and antimicrobial susceptibility testing.

Level 2 Hospitals

Level 2 hospitals should have an expanded bacteriology and mycology testing capability.

The package includes testing of:

  • urine;

  • tissue;

  • aspirated pus;

  • sputum;

  • deep respiratory specimens;

  • stool;

  • serum and plasma.

Examples include:

  • culture and identification of bacterial and yeast isolates;

  • antimicrobial susceptibility testing;

  • Histoplasma antigen testing;

  • potassium hydroxide microscopy for fungi;

  • Clostridioides difficile rapid testing;

  • Helicobacter pylori antigen testing;

  • Aspergillus antibody testing.

Level 3 Hospitals

The most complex testing is assigned to Level 3 hospitals.

WHO includes capabilities such as:

  • culture and identification of filamentous and dimorphic fungi;

  • testing for difficult-to-identify bacteria;

  • testing for high-biosafety-risk organisms;

  • Neisseria gonorrhoeae culture and susceptibility testing;

  • nucleic acid amplification tests;

  • minimum inhibitory concentration testing;

  • antifungal susceptibility testing;

  • phenotypic and genotypic detection of bacterial resistance mechanisms;

  • Pneumocystis jirovecii molecular testing;

  • Aspergillus antigen testing.

These capabilities generally require specialised infrastructure, highly trained personnel and stronger laboratory quality systems.

Rapid, Culture, Microscopy and Molecular Methods

The EPD–AMR includes a broad range of IVD technologies.

These include:

  • rapid diagnostic tests;

  • immunoassays;

  • serology;

  • microscopy;

  • bacterial culture;

  • fungal culture;

  • organism identification;

  • antimicrobial susceptibility testing;

  • molecular diagnostics.

WHO stresses that molecular diagnostics should complement rather than replace foundational microbiological methods.

Culture and AST Remain Essential

Despite rapid growth in molecular diagnostics, WHO emphasises that traditional microbiology remains essential.

Microscopy, culture and antimicrobial susceptibility testing can provide broader information and remain important for:

  • unexpected pathogen detection;

  • resistance surveillance;

  • diagnostic stewardship;

  • identification of organisms not covered by specific molecular assays.

This is particularly important for antimicrobial resistance programmes.

Antifungal Susceptibility Testing Added

The scope includes a limited number of additional tests beyond the current EDL.

One notable addition is antifungal susceptibility testing.

At Level 3 hospitals, WHO recommends antifungal susceptibility testing for selected fungal isolates, including filamentous fungi where appropriate.

Helicobacter pylori Antigen Testing

The package also introduces an antigen test for Helicobacter pylori as an additional test beyond the current EDL framework.

The Level 2 package includes stool antigen testing for H. pylori.

WHO notes that this test is proposed for inclusion in future versions of the EDL.

Testing Should Not Depend Only on On-Site Capacity

A key principle is that patients should still have access to required diagnostics even where the relevant testing capability is not physically available at the facility.

WHO states that where functional specimen referral systems can ensure correct transport and acceptable turnaround times, testing should be available regardless of local laboratory capacity.

This supports centralised and network-based testing models.

Hub-and-Spoke Laboratory Models

WHO specifically discusses centralised testing and diagnostic networks.

High-complexity testing may be concentrated at designated laboratories through a hub-and-spoke model, while lower-level facilities collect specimens and refer them for testing.

Hybrid approaches may also be appropriate.

For example, blood cultures may be incubated locally while positive samples are transferred to specialised laboratories for further identification and susceptibility testing.

Integration into National Essential Diagnostics Lists

WHO recommends integrating the EPD–AMR into national essential diagnostics lists rather than treating it as a standalone global prescription.

Countries should adapt the package according to:

  • disease burden;

  • local epidemiology;

  • laboratory capacity;

  • national health priorities;

  • available resources;

  • funding;

  • infrastructure;

  • existing diagnostic networks.

Four-Step National Implementation Framework

WHO proposes a structured implementation process.

Step 1 — Governance and Strategic Alignment

Countries should:

  • establish governance structures;

  • review national laboratory strategies;

  • map current infrastructure;

  • assess referral systems;

  • align the package with national diagnostic lists;

  • incorporate quality-management requirements.

Step 2 — Prioritisation

Countries should:

  • prioritise relevant tests;

  • consult key stakeholders;

  • develop a draft national package;

  • identify facilities suitable for early implementation.

Step 3 — Implementation Planning

Plans should cover:

  • laboratory infrastructure;

  • diagnostic networks;

  • procurement;

  • supply chains;

  • workforce;

  • training;

  • validation;

  • quality assurance;

  • monitoring and evaluation.

Step 4 — Scale-Up and Monitoring

Countries should then:

  • implement the package;

  • connect it with national AMR surveillance;

  • expand the national rollout;

  • monitor implementation;

  • periodically update the package.

Governance Must Include Multiple Stakeholders

WHO recommends a broad national governance structure involving:

  • Ministries of Health;

  • laboratory directorates;

  • national reference laboratories;

  • clinicians;

  • microbiologists;

  • civil society;

  • implementing partners;

  • funders.

This is intended to ensure that diagnostic scale-up aligns with broader health-system priorities.

Diagnostic and Antimicrobial Stewardship

WHO stresses that expanded access to diagnostics must be accompanied by diagnostic stewardship.

Testing should be ordered where clinically appropriate, and the entire diagnostic pathway should be considered, including:

  • test selection;

  • sample collection;

  • result interpretation;

  • reporting;

  • antimicrobial treatment decisions.

Increasing test availability without appropriate stewardship could lead to inefficient or inappropriate use.

Supply Chain Is a Critical Requirement

Diagnostic services depend on a continuous supply of:

  • reagents;

  • culture media;

  • consumables;

  • laboratory equipment.

WHO warns that many microbiology products have limited shelf lives or specific storage requirements.

Reliable supply chains and inventory systems are therefore essential to prevent interruptions in diagnostic services.

Quality Management and External Quality Assessment

WHO places strong emphasis on quality assurance.

Laboratories should implement:

  • quality-management systems;

  • standard operating procedures;

  • routine quality controls;

  • personnel training;

  • external quality assessment;

  • equipment maintenance;

  • confirmatory testing where appropriate.

Quality-management measures should be adapted to the level and complexity of testing.

Regulatory Approval Remains Relevant

Introduction of new tests should include structured verification to confirm performance and quality.

WHO specifically states that implementation should include appropriate regulatory approval.

This is particularly relevant for regulators and IVD manufacturers as countries expand diagnostic capacity.

Personnel and Competency Requirements

Bacteriology and mycology require specialised staff competencies.

These may include:

  • specimen processing;

  • microscopy;

  • media selection;

  • culture interpretation;

  • isolate identification;

  • susceptibility testing;

  • quality control;

  • reporting;

  • equipment maintenance.

WHO recommends incorporating workforce assessment and training into national implementation plans.

Equity Is a Core Principle

Implementation should also address inequities in diagnostic access.

WHO recommends considering differences related to:

  • geography;

  • gender;

  • age;

  • vulnerability;

  • clinical presentation;

  • access to care;

  • AMR risk.

The package therefore goes beyond laboratory planning and incorporates broader health-system equity objectives.

Development Included Global Consultation

WHO developed the EPD–AMR through consultations and surveys involving Member States, experts and the public.

The final package was reviewed and approved by:

  • the WHO Strategic Advisory Group of Experts on In Vitro Diagnostics;

  • the WHO Technical Advisory Group on Tuberculosis Diagnostics and Laboratory Strengthening.

288 Survey Respondents Across 85 Countries

WHO reports that 288 respondents from 85 countries participated in the development survey.

The group included:

  • 82 Member State representatives;

  • 29 experts;

  • 177 members of the public.

Participants represented all WHO regions and countries across multiple income levels.

Strong Support for the Proposed Tests

WHO reports broad agreement that the diagnostic tests included in the package would:

  • improve patient-important outcomes;

  • support mitigation of antimicrobial resistance;

  • inform AMR interventions.

Median priority scores were above 8 for all tests evaluated.

The charts in Annex 1 also show broad support across health-care levels for the proposed diagnostic package.

Implications for IVD Manufacturers

The EPD–AMR may become important for manufacturers of diagnostics used in:

  • clinical microbiology;

  • antimicrobial susceptibility testing;

  • bacterial identification;

  • fungal diagnostics;

  • rapid infectious-disease testing;

  • molecular resistance detection.

As countries adapt the WHO framework into national essential diagnostics lists and procurement programmes, the package may influence demand for specific diagnostic technologies.

Implications for Regulators

National regulators may also use the framework to inform:

  • prioritisation of essential IVDs;

  • regulatory capacity planning;

  • national diagnostic strategies;

  • emergency and public-health preparedness;

  • evaluation of diagnostic access gaps.

WHO explicitly identifies regulatory bodies among the intended audiences for the document.

Implications for Laboratory Networks

National laboratory systems will need to determine which tests should be:

  • decentralised;

  • performed locally;

  • centralised;

  • referred to higher-level laboratories.

The package encourages countries to combine tiered testing with strong referral networks rather than duplicating complex infrastructure at every facility.

A Minimum Package, Not a Comprehensive List

WHO stresses that the EPD–AMR is not intended to be a comprehensive list of every possible diagnostic test.

Instead, it represents a minimum package of priority diagnostics considered feasible, impactful and relevant to national health needs.

It also does not replace disease-specific WHO recommendations.

A Practical Framework for Expanding AMR Diagnostics

The new publication represents an important step in translating high-level commitments on antimicrobial resistance into practical diagnostic capacity.

By defining which tests should be available at different health-care levels, WHO provides governments, regulators, laboratories and health systems with a framework for strengthening:

  • diagnostic access;

  • bacteriology;

  • mycology;

  • antimicrobial susceptibility testing;

  • resistance detection;

  • laboratory networks;

  • surveillance systems.

For the IVD sector, the EPD–AMR also provides a clearer picture of the technologies that WHO considers essential for expanding global access to high-quality microbiology diagnostics.

Anterior
Anterior

WHO Publishes Toolkit of SOPs for Bacteriology, Mycology and Antimicrobial Susceptibility Testing

Próximo
Próximo

IMDRF Opens Call for Training Providers for New Endorsement Model Pilot